Table of contents
Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes. It contains the active substance insulin aspart, a rapid-acting insulin.
Fiasp : EPAR - Medicine overview (PDF/110.22 KB)
First published: 03/02/2017
Last updated: 26/08/2019
Fiasp : EPAR - Risk-management-plan summary (PDF/69.78 KB)
First published: 26/08/2019
Last updated: 15/06/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Novo Nordisk A/S
|Date of issue of marketing authorisation valid throughout the European Union||
18/08/2021 Fiasp - EMEA/H/C/004046 - R/0028
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Drugs used in diabetes
Insulins and analogues for injection, fast-acting
Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 201611/11/2016